Lensar Inc Stock Price, News & Analysis

LENSAR, a medical technology company, announced FDA clearance for its ALLY Adaptive Cataract Treatment System, marking a significant milestone. In Q2 2022, total revenue increased to $8.0 million, up 1% from Q2 2021, driven by a rise in U.S. procedure volumes despite lower LENSAR Laser System sales. Operating expenses rose by 37% to $7.6 million, attributed to higher marketing costs. The net loss for Q2 2022 widened to $6.8 million, compared to $4.4 million the previous year. Cash reserves stood at $25.2 million, with sufficient funds projected to sustain operations into 2024.

LENSAR, Inc. (NASDAQ: LNSR) will release its second quarter 2022 financial results on August 8, 2022, before market open. A conference call and webcast will follow at 8:30 am ET on the same day, where management will discuss the financial results and corporate highlights. The company specializes in advanced femtosecond laser surgical solutions for cataracts, notably with its ALLY™ Adaptive Cataract Treatment System, which enhances operational efficiency and surgical outcomes.

LENSAR, Inc. (NASDAQ: LNSR) announced FDA 510(k) clearance for its innovative ALLY Adaptive Cataract Treatment System. This system enables seamless femtosecond-laser-assisted cataract surgery (FLACS) in a single sterile environment. The company plans to begin a controlled launch in Q3 2023, with broader availability anticipated later this year. The ALLY System's technology includes Adaptive Intelligence to optimize cataract procedures, aiming to enhance surgical efficiency and patient outcomes. Over 125 surgeons have already had hands-on experience with the system, indicating positive reception.

LENSAR, Inc. (Nasdaq: LNSR) reported a 33% revenue increase to $9.3 million for Q1 2022, driven by a 38% rise in procedure volume to 38,901. The CEO expressed optimism about the forthcoming ALLY Adaptive Cataract Treatment System, which has received FDA acceptance for its 510(k) application and is expected to launch this year. However, the net loss widened to $6.7 million from $5.2 million year-over-year. R&D expenses surged 74% due to ALLY's development costs, while cash reserves decreased to $29 million, indicating the need for careful cash management going forward.

LENSAR, Inc. (NASDAQ: LNSR) will announce its first quarter 2022 financial results before market open on May 9, 2022. A conference call and webcast will follow at 8:30 am ET, where management will discuss financial outcomes and corporate highlights. LENSAR specializes in advanced femtosecond laser systems for cataract treatment, integrating proprietary technologies aimed at enhancing surgical efficiency and visual outcomes.

LENSAR reported a 31% increase in 2021 revenue, reaching $34.5 million, driven by a 37% rise in procedure volume in Q4. The company submitted the ALLY™ 510(k) application to the FDA, aiming for a commercial launch later this year. While fourth-quarter revenue hit $11.2 million, the net loss improved to ($3.9 million) from ($6.8 million) year-over-year. Cash and cash equivalents were $31.6 million, a decrease from $40.6 million the previous year. Operating expenses declined due to lower stock-based compensation, despite increased R&D spending.

LENSAR, Inc. (NASDAQ: LNSR) announced FDA acceptance of its 510(k) submission for the ALLY™ Adaptive Cataract Treatment System. This submission marks a key milestone in its two-step commercialization strategy, aimed at enhancing cataract surgery with improved technology. The company plans to file an additional application for phacoemulsification features later in 2022. If cleared, LENSAR expects to launch the ALLY system in the second half of 2022, which may optimize surgical efficiency and patient outcomes, according to CEO Nick Curtis.

LENSAR, Inc. (LNSR), a medical technology company specializing in femtosecond laser systems for cataract treatment, will release its Q4 2021 and full year results on March 3, 2022, before the market opens. A conference call with management will follow at 8:30am ET the same day, accessible via phone or webcast through the company's website. LENSAR is committed to enhancing surgical outcomes with its innovative laser solutions, designed to improve efficiency and precision in cataract surgeries.

LENSAR, Inc. (NASDAQ: LNSR), a medical technology company specializing in femtosecond laser solutions for cataract treatment, will have CEO Nick Curtis participate in two investor conferences. The first is the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16 at 9:30 a.m. ET, and the second is the 11th Annual SVB Leerink Global Healthcare Conference on February 17 at 2:20 p.m. ET. The SVB Leerink chat can be accessed via LENSAR's website, and the recording will be available for a month post-event.